Format

Send to

Choose Destination
Invest New Drugs. 2018 Dec;36(6):1158. doi: 10.1007/s10637-018-0679-5.

Correction to: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.

Author information

1
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University, 2220 Pierce Avenue, PRB 777, Nashville, TN, 37232, USA. laura.goff@vumc.org.
2
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. laura.goff@vumc.org.
3
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
4
Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
5
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University, 2220 Pierce Avenue, PRB 777, Nashville, TN, 37232, USA.
6
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
7
Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
8
Karmanos Cancer Institute, Detroit, MI, USA.
9
Rutgers Canter Institute, New Brunswick, NJ, USA.
10
University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA.

Abstract

The authors would like to note that the investigator affiliations have been corrected to reflect the actual affiliations of each author. The authors would also like to note an amendment to the first name of the second author. Nilo Azad was changed to reflect the full name of the author, which is Nilofer S. Azad as shown above. The original article has been corrected.

PMID:
30334109
DOI:
10.1007/s10637-018-0679-5

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center